TaiMed Biologics Inc. (TPEX:4147)
Taiwan
· Delayed Price · Currency is TWD 48.05
-0.25 (-0.52%)
Apr 28, 2026, 1:30 PM CST
TaiMed Biologics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 611.35 | 610.16 | 491.78 | 563.01 | 413.44 | Upgrade
|
| Revenue Growth (YoY) | 0.19% | 24.07% | -12.65% | 36.18% | -42.77% | Upgrade
|
| Cost of Revenue | 351.9 | 398.94 | 266.54 | 347.3 | 329.49 | Upgrade
|
| Gross Profit | 259.45 | 211.23 | 225.23 | 215.71 | 83.96 | Upgrade
|
| Selling, General & Admin | 72.26 | 75.29 | 97.19 | 74.45 | 109.72 | Upgrade
|
| Research & Development | 381.84 | 388.21 | 294.28 | 333.12 | 460.6 | Upgrade
|
| Operating Expenses | 454.1 | 463.49 | 391.46 | 407.57 | 570.32 | Upgrade
|
| Operating Income | -194.65 | -252.27 | -166.23 | -191.86 | -486.37 | Upgrade
|
| Interest Expense | -10.71 | -12.6 | -14.81 | -10.1 | -7.44 | Upgrade
|
| Interest & Investment Income | 28.94 | 33.97 | 8.46 | 4.34 | 4.03 | Upgrade
|
| Currency Exchange Gain (Loss) | 6.49 | 26.35 | 2.04 | 48.69 | -11.38 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.46 | 5.05 | 4.78 | 2.44 | 3.45 | Upgrade
|
| EBT Excluding Unusual Items | -165.48 | -199.51 | -165.76 | -146.48 | -497.7 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.69 | - | -29.05 | -122.81 | 26.76 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.61 | -2.32 | - | - | 0.01 | Upgrade
|
| Pretax Income | -167.78 | -201.83 | -194.81 | -269.29 | -470.93 | Upgrade
|
| Net Income | -167.78 | -201.83 | -194.81 | -269.29 | -470.93 | Upgrade
|
| Net Income to Common | -167.78 | -201.83 | -194.81 | -269.29 | -470.93 | Upgrade
|
| Shares Outstanding (Basic) | 273 | 268 | 253 | 252 | 252 | Upgrade
|
| Shares Outstanding (Diluted) | 273 | 268 | 253 | 252 | 252 | Upgrade
|
| Shares Change (YoY) | 1.85% | 6.08% | 0.18% | 0.04% | 0.03% | Upgrade
|
| EPS (Basic) | -0.61 | -0.75 | -0.77 | -1.07 | -1.87 | Upgrade
|
| EPS (Diluted) | -0.61 | -0.75 | -0.77 | -1.07 | -1.87 | Upgrade
|
| Free Cash Flow | 168.48 | -387.61 | -31.75 | -608.77 | -220.96 | Upgrade
|
| Free Cash Flow Per Share | 0.62 | -1.45 | -0.13 | -2.41 | -0.88 | Upgrade
|
| Gross Margin | 42.44% | 34.62% | 45.80% | 38.31% | 20.31% | Upgrade
|
| Operating Margin | -31.84% | -41.34% | -33.80% | -34.08% | -117.64% | Upgrade
|
| Profit Margin | -27.44% | -33.08% | -39.61% | -47.83% | -113.90% | Upgrade
|
| Free Cash Flow Margin | 27.56% | -63.52% | -6.46% | -108.13% | -53.44% | Upgrade
|
| EBITDA | -46.5 | -104.49 | -17.72 | -42.22 | -336.3 | Upgrade
|
| EBITDA Margin | -7.61% | -17.13% | -3.60% | -7.50% | -81.34% | Upgrade
|
| D&A For EBITDA | 148.15 | 147.78 | 148.51 | 149.64 | 150.07 | Upgrade
|
| EBIT | -194.65 | -252.27 | -166.23 | -191.86 | -486.37 | Upgrade
|
| EBIT Margin | -31.84% | -41.34% | -33.80% | -34.08% | -117.64% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.